Eli Lilly

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Eli Lilly 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About LLY

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. 

CEO
David A. Ricks
CEODavid A. Ricks
Employees
50,000
Employees50,000
Headquarters
Indianapolis, Indiana
HeadquartersIndianapolis, Indiana
Founded
1876
Founded1876
Employees
50,000
Employees50,000

LLY Key Statistics

Market cap
1.07T
Market cap1.07T
Price-Earnings ratio
38.68
Price-Earnings ratio38.68
Dividend yield
0.59%
Dividend yield0.59%
Average volume
2.32M
Average volume2.32M
High today
$1,161.00
High today$1,161.00
Low today
$1,140.62
Low today$1,140.62
Open price
$1,154.93
Open price$1,154.93
Volume
849.36K
Volume849.36K
52 Week high
$1,292.65
52 Week high$1,292.65
52 Week low
$712.05
52 Week low$712.05

Stock Snapshot

Eli Lilly(LLY) stock is priced at $1,140.96, giving the company a market capitalization of 1.07T. It carries a P/E multiple of 38.68 and pays a dividend yield of 0.59%.

On 2026-09-15, Eli Lilly(LLY) stock traded between a low of $1,140.62 and a high of $1,161.00. Shares are currently priced at $1,140.96, which is +0.0% above the low and -1.7% below the high.

The Eli Lilly(LLY)'s current trading volume is 849.36K, compared to an average daily volume of 2.32M.

During the past year, Eli Lilly(LLY) stock moved between $712.05 at its lowest and $1,292.65 at its peak.

During the past year, Eli Lilly(LLY) stock moved between $712.05 at its lowest and $1,292.65 at its peak.

LLY News

24/7 Wall St. 1h
Novo Nordisk Expands Obesity Drug to Children, But Market Hesitates on Adoption

Investing Novo Nordisk Expands Obesity Drug to Children, But Market Hesitates on Adoption A landmark trial just proved semaglutide can pull children as young as...

Novo Nordisk Expands Obesity Drug to Children, But Market Hesitates on Adoption
Nasdaq 2h
Broker Darlings of the Dow: Johnson & Johnson Ranks As a Top 15 Analyst Pick

A study of analyst recommendations at the major brokerages shows that Johnson & Johnson (Symbol: JNJ) is the #10 broker pick, on average, out of the 30 stocks m...

Broker Darlings of the Dow: Johnson & Johnson Ranks As a Top 15 Analyst Pick
Seeking Alpha 4h
Eli Lilly boosted to Buy at Berenberg as upside to 2026 guidance seen

Berenberg upgraded Eli Lilly (LLY) to Buy from Hold, saying that it sees the drugmaker exceeding its 2026 guidance driven by continuing its lead in the weight-l...

Eli Lilly boosted to Buy at Berenberg as upside to 2026 guidance seen

Analyst ratings

84%

of 32 ratings
Buy
84.4%
Hold
9.4%
Sell
6.3%

More LLY News

Benzinga 4h
Eli Lilly Stock Gains as Retatrutide and Foundayo Data Highlight Pipeline Strength

Shares of Eli Lilly and Company (NYSE:LLY) are trading higher Tuesday morning following positive previews of its late-stage obesity and diabetes pipeline. Eli...

Eli Lilly Stock Gains as Retatrutide and Foundayo Data Highlight Pipeline Strength
24/7 Wall St. 5h
There Are Plenty of Eli Lilly Bulls: Here's What They Aren't Telling You

Investing There Are Plenty of Eli Lilly Bulls: Here’s What They Aren’t Telling You Eli Lilly's bulls are pointing at a 47% revenue surge and a pipeline loaded w...

There Are Plenty of Eli Lilly Bulls: Here's What They Aren't Telling You
Nasdaq 5h
LB Pharmaceuticals Appoints Susan Kozauer As CMO

(RTTNews) - LB Pharmaceuticals Inc. (LBRX), a neuromedicines company, on Tuesday appointed Susan Kozauer as Chief Medical Officer. Kozauer most recently served...

LB Pharmaceuticals Appoints Susan Kozauer As CMO
24/7 Wall St. 5h
Eli Lilly Vs. Merck: One is a No-Brainer to Hold Through 2030

Investing Eli Lilly Vs. Merck: One is a No-Brainer to Hold Through 2030 Eli Lilly and Merck both reported second quarter earnings, and the contrast could not be...

Eli Lilly Vs. Merck: One is a No-Brainer to Hold Through 2030
TipRanks 9h
Eli Lilly upgraded to Buy from Hold at Berenberg

Berenberg upgraded Eli Lilly (LLY) to Buy from Hold with a price target of $1,400, up from $1,220. The firm says its 2026 return on investment analysis confirms...

TipRanks 1d
Lilly Refines Abemaciclib Delivery in New Phase 1 Study, Supporting Long-Term Oncology Strategy

Eli Lilly And Company (LLY) announced an update on their ongoing clinical study. The study, officially titled “A Phase 1, Open-Label, Randomized, Crossover Stu...

MarketWatch 1d
Novo drops ‘Nordisk’ in corporate refresh to take on Lilly in the weight-loss wars

Novo Nordisk, the Danish drug giant behind Ozempic, is streamlining its corporate culture and shortening its name as it tries to better compete in the market fo...

Novo drops ‘Nordisk’ in corporate refresh to take on Lilly in the weight-loss wars

People also own

Based on the portfolios of people who own LLY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.